Literature DB >> 31264832

Activity-Guided Design of HDAC11-Specific Inhibitors.

Se In Son1, Ji Cao1, Cheng-Liang Zhu1, Seth P Miller1, Hening Lin1,2.   

Abstract

Mammalian histone deacetylases (HDACs) are a class of enzymes that play important roles in biological pathways. Existing HDAC inhibitors target multiple HDACs without much selectivity. Inhibitors that target one particular HDAC will be useful for investigating the biological functions of HDACs and for developing better therapeutics. Here, we report the development of HDAC11-specific inhibitors using an activity-guided rational design approach. The enzymatic activity and biological function of HDAC11 have been little known, but recent reports suggest that it has efficient defatty-acylation activity and that inhibiting it could be useful for treating a variety of human diseases, including viral infection, multiple sclerosis, and metabolic diseases. Our best inhibitor, SIS17, is active in cells and inhibited the demyristoylation of a known HDAC11 substrate, serine hydroxymethyl transferase 2, without inhibiting other HDACs. The activity-guided design may also be useful for the development of isoform-specific inhibitors for other classes of enzymes.

Entities:  

Year:  2019        PMID: 31264832      PMCID: PMC6893910          DOI: 10.1021/acschembio.9b00292

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  22 in total

Review 1.  HDAC inhibitor therapy in autoimmunity and transplantation.

Authors:  Wayne W Hancock; Tatiana Akimova; Ulf H Beier; Yujie Liu; Liqing Wang
Journal:  Ann Rheum Dis       Date:  2012-04       Impact factor: 19.103

Review 2.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

3.  HDAC11 is a novel drug target in carcinomas.

Authors:  Hedwig E Deubzer; Marie C Schier; Ina Oehme; Marco Lodrini; Bernard Haendler; Anette Sommer; Olaf Witt
Journal:  Int J Cancer       Date:  2012-10-25       Impact factor: 7.396

4.  HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.

Authors:  Daniela Buglio; Noor M Khaskhely; Kui Shin Voo; Hector Martinez-Valdez; Yong-Jun Liu; Anas Younes
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

5.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.

Authors:  M S Finnin; J R Donigian; A Cohen; V M Richon; R A Rifkind; P A Marks; R Breslow; N P Pavletich
Journal:  Nature       Date:  1999-09-09       Impact factor: 49.962

6.  Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.

Authors:  Lin Gao; Maria A Cueto; Fred Asselbergs; Peter Atadja
Journal:  J Biol Chem       Date:  2002-04-10       Impact factor: 5.157

7.  HDAC8 Catalyzes the Hydrolysis of Long Chain Fatty Acyl Lysine.

Authors:  Pornpun Aramsangtienchai; Nicole A Spiegelman; Bin He; Seth P Miller; Lunzhi Dai; Yingming Zhao; Hening Lin
Journal:  ACS Chem Biol       Date:  2016-08-05       Impact factor: 5.100

8.  Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.

Authors:  Matthew W Martin; Jennifer Y Lee; David R Lancia; Pui Yee Ng; Bingsong Han; Jennifer R Thomason; Maureen S Lynes; C Gary Marshall; Chiara Conti; Alan Collis; Monica Alvarez Morales; Kshama Doshi; Aleksandra Rudnitskaya; Lili Yao; Xiaozhang Zheng
Journal:  Bioorg Med Chem Lett       Date:  2018-05-09       Impact factor: 2.823

9.  Programming and Regulation of Metabolic Homeostasis by HDAC11.

Authors:  Lei Sun; Caralina Marin de Evsikova; Ka Bian; Alexandra Achille; Elphine Telles; Huadong Pei; Edward Seto
Journal:  EBioMedicine       Date:  2018-06-28       Impact factor: 8.143

10.  HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2.

Authors:  Ji Cao; Lei Sun; Pornpun Aramsangtienchai; Nicole A Spiegelman; Xiaoyu Zhang; Weishan Huang; Edward Seto; Hening Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-28       Impact factor: 11.205

View more
  5 in total

1.  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors:  Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

2.  Garcinol Is an HDAC11 Inhibitor.

Authors:  Se In Son; Dan Su; Thanh Tu Ho; Hening Lin
Journal:  ACS Chem Biol       Date:  2020-10-09       Impact factor: 5.100

Review 3.  Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives.

Authors:  Mohammed Ghiboub; Ahmed M I Elfiky; Menno P J de Winther; Nicola R Harker; David F Tough; Wouter J de Jonge
Journal:  J Pers Med       Date:  2021-04-23

4.  Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors.

Authors:  Zsófia Kutil; Jana Mikešová; Matthes Zessin; Marat Meleshin; Zora Nováková; Glenda Alquicer; Alan Kozikowski; Wolfgang Sippl; Cyril Bařinka; Mike Schutkowski
Journal:  ACS Omega       Date:  2019-11-15

Review 5.  The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.

Authors:  Guo Li; Yuan Tian; Wei-Guo Zhu
Journal:  Front Cell Dev Biol       Date:  2020-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.